Premium
Neoadjuvant selpercatinib for advanced medullary thyroid cancer
Author(s) -
Jozaghi Yelda,
Zafereo Mark,
Williams Michelle D.,
GuleMonroe Maria K.,
Wang Jennifer,
Grubbs Elizabeth G.,
Vaporciyan Ara,
Hu Mimi I.,
Busaidy Naifa,
Dadu Ramona,
Waguespack Steven G.,
Subbiah Vivek,
Cabanillas Maria
Publication year - 2021
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26527
Subject(s) - medicine , medullary thyroid cancer , calcitonin , oncology , clinical trial , disease , thyroid cancer , cancer , targeted therapy , thyroid , cabozantinib , food and drug administration , neoadjuvant therapy , medullary cavity , pharmacology , breast cancer
Abstract Background Targeted kinase inhibitors have been increasingly utilized in the treatment of advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next generation selective RET inhibitors have been clinically validated, and selpercatinib was recently Food and Drug Administration (FDA)‐approved for advanced MTC. The advent of highly selective, potent RET inhibitors is broadening the treatment options for patients with RET ‐mutated cancers. Methods We report the first published case of neoadjuvant selpercatinib followed by surgery for a patient with initially unresectable, widely metastatic, RET ‐mutated MTC who was treated on a single patient protocol. Results After greater than 50% RECIST response, the patient underwent complete surgical resection followed by selpercatinib resumption. He remains locoregionally disease‐free 21 months after starting therapy with stable metastatic disease (after initial partial response); and calcitonin/CEA continue to decline. Conclusion This novel treatment strategy for locoregionally advanced RET‐mutated MTC warrants further study in clinical trials.